Lipocine Inc. Announces Milestone Payment from Abbott Laboratories (ABT)  
4/20/2010 9:48:41 AM

SALT LAKE CITY--(BUSINESS WIRE)--Lipocine Inc. ( announced today the receipt of a $2 million development milestone payment from Abbott under the terms of its Licensing Agreement to develop and commercialize an oral testosterone product for hypogonadism, also known as low testosterone (low T).